Vimarsana
Biggest News Aggregation in the World

Testing Service Center News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Testing Service Center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Testing Service Center Today - Breaking & Trending Today

BK Technologies Corporation: BK Technologies BKR 5000 Approved by U.S. Department of the Interior - Vimarsana News

BK Technologies Corporation: BK Technologies BKR 5000 Approved by U.S. Department of the Interior

BK Technologies Corporation: BK Technologies BKR 5000 Approved by U.S. Department of the Interior WEST MELBOURNE, FL / ACCESSWIRE / April 1, 2021 / BK Technologies Corporation (NYSE American:BKTI) today announced it has received approval from the U.S. Department of the Interior (DOI) for its BKR 5000 Digital P25 communications technology. BK President Tim Vitou commented, "We are pleased to complement our recent NIFC Fire Approval with the DOI's favorable test results, providing the necessary approval for DOI agency purchases, including high-risk fire and law enforcement use. Our Engineering ...

Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug - Vimarsana News

Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug

Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the "British variant"), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University's Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center. The virus variant was labeled "Variant of Concern 202012/01" by Public Health England (PHE), an agency o...

NAU to test Allarity drug against highly infectious Coronavirus Variant B117 - Vimarsana News

NAU to test Allarity drug against highly infectious Coronavirus Variant B117

 E-Mail Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the "British variant"), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University's Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center. The virus variant was labelled "Variant of Concern 202012/01" by Public Health England (PHE), an agency of the UK Department of Health and Social Care, in a publication on Decembe...